GOLETA, CA – Medtrade exhibitor Inogen, Inc., a medical technology company offering respiratory products for use in the homecare setting, revealed revenue of $92.3 million, a year-over-year increase of 4.0% for the second quarter ended June 30, 2025.

Inogen delivered adjusted EBITDA of $2.1 million, the second consecutive quarter of positive adjusted EBITDA, plus $4.4 million in operating cash flow in the second quarter of 2025.

The California-based company introduced Voxi™ 5, a new stationary oxygen concentrator (SOC) designed to improve access to quality oxygen therapy for long-term care patients in the U.S., further expanding the portfolio. A new patient portal debuted to helppatients with seamless self-service to manage insurance details, order accessories, and access to on-demand support tools.

“We are executing a compelling turnaround strategy, delivering six consecutive quarters of mid-single-digit revenue growth and two quarters of positive adjusted EBITDA,” said Kevin Smith, president and CEO. “Our 4% year-over-year revenue growth in the second quarter reflects the strength of our commercial execution and operational enhancements. Given our strong first-half performance, we are raising full-year revenue guidance. We remain confident in our long-term value creation strategy as we continue to drive innovation and position Inogen as a leader in comprehensive respiratory care.”